Searched for
LANREOTIDE INJECTION
Sun Pharma, Cipla recall products in US over manufacturing issues: USFDASun Pharma and Cipla, two leading drug manufacturers from India, are taking precautionary measures by recalling products in the United Stat...- Cipla shares slide 5% after temporary halt in key drug manufacturingCipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek partner. Supply ...
- Cipla Q3 preview: Up to 7% YoY uptick seen in revenue. Margins to fall on a YoY and sequential basisCipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth. Brokerages have differi...
- Cipla gets USFDA nod to market Lanreotide injectionCipla has received approval from the US FDA to market its Lanreotide injection, a generic medication for treating acromegaly and other cond...
- Fundamental Radar | Cipla upgraded to “buy” on 5 major growth tailwinds: Motilal OswalCipla recorded an 8% growth in sales on the back of the launch of the generic version of Revlimid and gained market share in lanreotide, al...
- Buy Cipla, target price Rs 1260: Axis SecuritiesCipla, incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 86522.68 Crore) operating in Pharmaceuticals sector.
- Buy Cipla, target price Rs 1058: ICICI SecuritiesCipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 73066.96 Crore) operating in Pharmaceuticals s...
- Sun, Cipla and Gland remain top pharma picks in 2022: Nithya Balasubramanian“In terms of the sector, I would say it is back to basics. I would not recommend a pure Covid play at all.“
- Cipla gains 3% on USFDA nod to market Lanreotide"This approval is a significant step for our US business and is in line with our aspiration to continue growth in our complex product pipel...
- Stocks in the news: Shriram Properties, Airtel, Zomato, ITC and Future GroupShriram Properties, the south India-based real estate player, will make its Dalal Street Debut on Monday. It sold its shares in the range o...
- Cipla receives USFDA nod to market Lanreotide injection in American marketThe company said it has received final approval for Lanreotide Injection from the US Food and Drug Administration (USFDA). The FDA approval...
Load More
